IP Library Patent Application 14555036
Patent Application
App. No. 14/555,036

METHOD OF NUCLEIC ACID AMPLIFICATION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/555,036
Abstract

A nucleic acid molecule can be annealed to an appropriate immobilized primer. The primer can then be extended and the molecule and the primer can be separated from one another. The extended primer can then be annealed to another immobilized primer and the other primer can be extended. Both extended primers can then be separated from one another and can be used to provide further extended primers. The process can be repeated to provide amplified, immobilized nucleic acid molecules. These can be used for many different purposes, including sequencing, screening, diagnosis, in situ nucleic acid synthesis, monitoring gene expression, nucleic acid fingerprinting, etc.

Claims (31)

1 . (canceled)

2 . A multiplex method for determining the presence of one or more target polynucleotide sequences across a plurality of samples, comprising:

amplifying and tagging target polynucleotides by PCR in each of said plurality of samples with an amplification primer comprising a high throughput sequencing adaptor, a sample-specific tag sequence, and a priming sequence to amplify said target polynucleotide sequence(s);

combining the amplified polynucleotides and sequencing the polynucleotide pool in high throughput, so as to determine the sequence of at least 100 tagged polynucleotides for each of said samples;

assigning the nucleotide sequences to the originating samples by the nucleotide sequence of the sample-specific tag, thereby determining the presence of the target polynucleotide sequence(s) across the samples.

3 . The method of claim 2 , wherein the samples are diagnostic.

4 . The method of claim 2 , wherein the samples are biological samples.

5 . The method of claim 2 , wherein the target polynucleotides are genomic DNA or mitochondrial DNA.

6 . The method of claim 2 , wherein the target polynucleotides are cDNA.

7 . The method of claim 2 , wherein the number of samples is over 10.

8 . The method of claim 2 , wherein the number of samples is over 100.

9 . The method of claim 2 , wherein the priming sequence is the same across samples.

10 . The method of claim 2 , wherein the sequencing adaptor immobilizes the individual polynucleotides for clonal amplification and sequencing.

11 . The method of claim 10 , wherein the sequencing is sequencing-by-synthesis, sequencing-by-ligation, or sequencing-by-hybridization.

12 . The method of claim 2 , wherein the PCR amplifications employ a forward and reverse primer that both comprise the high throughput sequencing adaptor and the sample-specific tag.

13 . A method for simultaneously determining the sequence of one or more sequences of interest in a plurality of samples, comprising:

amplifying and tagging polynucleotide sequences of interest by PCR in each of said plurality of samples with an amplification primer comprising a sequence complementary to a sequencing primer for high throughput sequencing, a tag sequence which is different for each sample, and primer sequences surrounding the specific sequences of interest to amplify said specific sequences of interest;

sequencing the amplified polynucleotide sequences of interest from the plurality of samples in high throughput, so as to determine the sequence of over 100 different sequences from the plurality of samples; and

identifying the origin of the amplified polynucleotide sequences of interest using the tag sequence which is different for each sample.

14 . The method of claim 13 , wherein the over 100 different sequences are from each of the plurality of samples.

15 . The method of claim 13 , wherein the method is for diagnosis.

16 . The method of claim 13 , wherein the samples are biological samples.

17 . The method of claim 13 , wherein the polynucleotide sequences of interest are genomic DNA or mitochondrial DNA.

18 . The method of claim 13 , wherein the polynucleotide sequences of interest are cDNA.

19 . The method of claim 13 , wherein the number of samples is over 10.

20 . The method of claim 13 , wherein the number of samples is over 100.

21 . The method of claim 13 , wherein the primer sequences surrounding the specific sequences of interest to amplify said specific sequences of interest is the same across samples.

22 . The method of claim 13 , wherein the sequence complementary to a sequencing primer for high throughput sequencing immobilizes the individual polynucleotides for clonal amplification and sequencing.

23 . The method of claim 22 , wherein the sequencing is sequencing-by-synthesis, sequencing-by-ligation, or sequencing-by-hybridization.

24 . The method of claim 13 , wherein the PCR amplifications employ a forward and reverse primer that both comprise the sequence complementary to a sequencing primer for high throughput sequencing and the tag sequence which is different for each sample.

25 . The method of claim 13 , wherein over 1000 different sequences from the plurality of samples are determined.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2015
From: GLAXO GROUP LIMITED
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 036861/0796 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2015
From: SMITHKLINE BEECHAM CORPORATION
To: MANTEIA SA
Reel/Frame 036861/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2015
From: MANTEIA SA
To: SOLEXA LTD.; LYNX THERAPEUTICS INC.
Reel/Frame 036861/0823 →
MERGER Recorded Oct 22, 2015
From: SOLEXA, INC.
To: ILLUMINA, INC.
Reel/Frame 036861/0848 →
CHANGE OF NAME Recorded Oct 22, 2015
From: SOLEXA LIMITED
To: ILLUMINA CAMBRIDGE LIMITED
Reel/Frame 036861/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2015
From: KAWASHIMA, ERIC H.; FARINELLI, LAURENT; MAYER, PASCAL
To: GLAXO GROUP LIMITED
Reel/Frame 036931/0981 →
CHANGE OF NAME Recorded Oct 22, 2015
From: LYNX THERAPEUTICS INC.
To: SOLEXA, INC.
Reel/Frame 036932/0032 →